CL2015002545A1 - Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a. - Google Patents

Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a.

Info

Publication number
CL2015002545A1
CL2015002545A1 CL2015002545A CL2015002545A CL2015002545A1 CL 2015002545 A1 CL2015002545 A1 CL 2015002545A1 CL 2015002545 A CL2015002545 A CL 2015002545A CL 2015002545 A CL2015002545 A CL 2015002545A CL 2015002545 A1 CL2015002545 A1 CL 2015002545A1
Authority
CL
Chile
Prior art keywords
type
inhibitor compounds
phosphodiesterase inhibitor
new phosphodiesterase
new
Prior art date
Application number
CL2015002545A
Other languages
English (en)
Inventor
Hervé Geneste
Michael Ochse
Karla Drescher
Katja Jantos
Jayne Froggett
Clarissa Jakob
Jürgen Dinges
Original Assignee
Abbvie Inc
Abbvie Deutschland Gmbh & Co Kgf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50241454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002545(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc, Abbvie Deutschland Gmbh & Co Kgf filed Critical Abbvie Inc
Publication of CL2015002545A1 publication Critical patent/CL2015002545A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epidemiology (AREA)

Abstract

COMPUESTOS DERIVADOS HETEROCICLICOS Y SUS SALES, COMO INHIBIDORES DE LA FOSFODIESTERASA DEL TIPO 10A; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE, UTIL PARA TRATAR TRASTORNOS NEUROLOGICOS Y PSIQUIATRICOS TALES COMO ESQUIZOFRENIA, TRASTORNOS BIPOLARES, DEPRESION, ENFERMEDAD DE ALZHEIMER, ENTRE OTROS.
CL2015002545A 2013-03-13 2015-09-09 Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a. CL2015002545A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361779141P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
CL2015002545A1 true CL2015002545A1 (es) 2016-07-22

Family

ID=50241454

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002545A CL2015002545A1 (es) 2013-03-13 2015-09-09 Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a.

Country Status (22)

Country Link
US (1) US9200005B2 (es)
EP (1) EP2970328B1 (es)
JP (1) JP2016510786A (es)
KR (1) KR20150127724A (es)
CN (1) CN105358561A (es)
AR (1) AR095267A1 (es)
AU (1) AU2014230825A1 (es)
BR (1) BR112015022094A2 (es)
CA (1) CA2902654A1 (es)
CL (1) CL2015002545A1 (es)
CR (1) CR20150496A (es)
DO (1) DOP2015000214A (es)
HK (1) HK1219273A1 (es)
IL (1) IL240593A0 (es)
MX (1) MX2015012389A (es)
PE (1) PE20160040A1 (es)
PH (1) PH12015501962A1 (es)
RU (1) RU2015143536A (es)
SG (1) SG11201507380PA (es)
TW (1) TW201441230A (es)
UY (1) UY35393A (es)
WO (1) WO2014140086A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
WO2016036954A1 (en) * 2014-09-05 2016-03-10 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
CN107406429B (zh) 2015-01-09 2021-07-06 基因泰克公司 哒嗪酮衍生物及其在治疗癌症中的用途
BR112019027717A2 (pt) * 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
CN115838364A (zh) * 2022-12-20 2023-03-24 河南沁朋科技有限公司 一种3,3-双噻吩的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200000318A (et) 1997-12-05 2001-08-15 Astrazeneca Uk Limited Uudsed ühendid
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
MXPA06014236A (es) 2004-06-07 2007-02-14 Pfizer Prod Inc Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad.
JP2008512375A (ja) 2004-09-03 2008-04-24 メモリ ファーマセチカル コーポレーション 精神医学的又は神経学的症候群の治療用のホスホジエステラーゼ１０阻害剤としての４−置換４，６−ジアルコキシ−シンノリン誘導体
JP2009504759A (ja) 2005-08-16 2009-02-05 メモリ ファーマセチカル コーポレーション ホスホジエステラーゼ１０阻害剤
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2007082546A1 (en) 2006-01-20 2007-07-26 H. Lundbeck A/S Use of tofisopam as a pde10a inhibitor
BRPI0707223A2 (pt) 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
JP2009527560A (ja) 2006-02-21 2009-07-30 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体
MX2008010671A (es) 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.
CA2641670A1 (en) 2006-02-23 2007-08-30 Pfizer Products Inc. Substituted quinazolines as pde10 inhibitors
CA2643044A1 (en) 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
WO2007103554A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
CA2654394A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
RS52562B (en) 2006-07-10 2013-04-30 H. Lundbeck A/S (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2009025823A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
WO2009025839A2 (en) 2007-08-22 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
US20090054434A1 (en) 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
TW200918519A (en) 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
US20090143392A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
CA2706986A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
AU2008329775A1 (en) 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
US20090143361A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
WO2009076454A2 (en) * 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8927718B2 (en) * 2009-08-26 2015-01-06 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
EP2632461A4 (en) 2010-10-29 2014-04-02 Merck Sharp & Dohme ISOINDOLINONE COMPOUNDS USEFUL AS PDE INHIBITORS 10
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a

Also Published As

Publication number Publication date
CR20150496A (es) 2016-02-19
US20140275069A1 (en) 2014-09-18
EP2970328A1 (en) 2016-01-20
CN105358561A (zh) 2016-02-24
JP2016510786A (ja) 2016-04-11
AU2014230825A1 (en) 2015-09-03
PH12015501962A1 (en) 2016-01-11
US9200005B2 (en) 2015-12-01
HK1219273A1 (zh) 2017-03-31
DOP2015000214A (es) 2015-12-31
EP2970328B1 (en) 2017-04-26
UY35393A (es) 2014-10-31
MX2015012389A (es) 2016-03-03
SG11201507380PA (en) 2015-10-29
IL240593A0 (en) 2015-09-24
WO2014140086A1 (en) 2014-09-18
RU2015143536A (ru) 2017-04-18
KR20150127724A (ko) 2015-11-17
CA2902654A1 (en) 2014-09-18
AR095267A1 (es) 2015-09-30
TW201441230A (zh) 2014-11-01
BR112015022094A2 (pt) 2018-06-12
PE20160040A1 (es) 2016-02-11

Similar Documents

Publication Publication Date Title
CL2015002545A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a.
CL2016002573A1 (es) Compuesto de ciclopropanamina y sus usos.
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
DOP2014000194A (es) COMPUESTOS DE OXAZOLIDIN- 2- ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
GT201700099A (es) 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1
SV2017005434A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CR20150425A (es) Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
ECSP17035415A (es) 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
DOP2014000230A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
DOP2014000253A (es) Inhibidores del nampt
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
GT201600132A (es) Derivados de ácido heteroaril butanóico como inhibidores de lta4h
CR20140553A (es) Compuestos de fenoxietil piperidina
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
BR112017009289A2 (pt) métodos de administrar composições de amantadina
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
UY37191A (es) Derivados de dibenzofurano para uso como inhibidores de bromodominio
CU20140102A7 (es) Compuestos de oxazolidin-2- ona y usos de los mismos como inhibidores de la p13ks
GT201500232A (es) Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos